Rhinomed confirmed that it's revolutionary new ProntoTM rechargeable, dual action, vapour release technology has been registered with the European Authority as a Class I medical device. Receiving a CE Mark allows the Pronto range to now be sold throughout the European Union. The receipt of the CE Mark for the Pronto range follows on from the recent announcement of US FDA approval and Australian TGA approval as a Class 1 device. This is another critical step in ensuring that the Pronto range can be sold globally and will further assist the company in its business development activities. Based on the company's existing BreatheAssistTMnasal dilator technology (MuteTM and TurbineTM), the new ProntoTM OTC range includes the novel AirstreamTM release system that allows a continuous release of an essential oil blend into the nasal airstream over a set period of time. By combining this new vapour release technology with the Mute's stenting action, Rhinomed provides users with a unique dual action device that not only improves nasal airflow but also delivers a soothing blend of pure essential oils traditionally known to help clear a stuffy nose or to help one sleep better naturally. Pronto also includes a novel recharging and storage case that allows Pronto to be recharged before each use. When Pronto is stored in its case in the recharge position, the Pronto device is replenished with the essential oil formulation so it is ready for use again.